Lipids in cell membranes regulate the activity of a cancer-linked protein, cell biologists at RIKEN have discovered. This ...

Henlius (2696.HK) held its 2025 Global R&D Day themed 'Collaborate to Create,' gathering senior executives, experts, and industry leaders to discuss R&D advances, strategic planning, and cutting-edge ...

A new study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.

This pathway is particularly important in cancer biology, where abnormal growth is a defining characteristic. In breast cancer, mTORC1 signaling ... progesterone, and HER2—that are typically ...

Vividion Therapeutics, Inc. has announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

1Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. 2Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria ...

The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.

The firm believes VVD-159642 has the potential to treat a broad patient population, including those with RAS- and HER2-overexpressed tumors.

This pathway is especially important in cancer biology, where abnormal growth is a hallmark. In breast cancer, mTORC1 signaling is disrupted ... progesterone, and HER2—that are usually targeted ...